Literature DB >> 26587050

Refining the approach to vaccines against influenza A viruses with pandemic potential.

Rita Czako1, Kanta Subbarao1.   

Abstract

Vaccination is the most effective strategy for prevention and control of influenza. Timely production and deployment of seasonal influenza vaccines is based on an understanding of the epidemiology of influenza and on global disease and virologic surveillance. Experience with seasonal influenza vaccines guided the initial development of pandemic influenza vaccines. A large investment in pandemic influenza vaccines in the last decade has resulted in much progress and a body of information that can now be applied to refine the established paradigm. Critical and complementary considerations for pandemic influenza vaccines include improved assessment of the pandemic potential of animal influenza viruses, proactive development and deployment of pandemic influenza vaccines, and application of novel platforms and strategies for vaccine production and administration.

Entities:  

Keywords:  antigenic mismatch; avian influenza; pandemic influenza; prepandemic vaccine; prime boost

Year:  2015        PMID: 26587050      PMCID: PMC4648374          DOI: 10.2217/fvl.15.69

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  171 in total

1.  Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up.

Authors:  I Persson; F Granath; J Askling; J F Ludvigsson; T Olsson; N Feltelius
Journal:  J Intern Med       Date:  2013-11-10       Impact factor: 8.989

2.  Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

Authors:  Karl G Nicholson; Catherine I Thompson; Jaco M Klap; John M Wood; Sally Batham; Robert W Newman; Robert Mischler; Maria C Zambon; Iain Stephenson
Journal:  Vaccine       Date:  2009-09-30       Impact factor: 3.641

3.  Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial.

Authors:  Shingo Uno; Kazuhiko Kimachi; Junko Kei; Keiichiro Miyazaki; Ayano Oohama; Tomohiro Nishimura; Kayo Ibaragi; Koichi Odoh; Yasuhiro Kudo; Yoichiro Kino
Journal:  Microbiol Immunol       Date:  2011-11       Impact factor: 1.955

4.  The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals.

Authors:  Amorsolo L Suguitan; Yumiko Matsuoka; Yuk-Fai Lau; Celia P Santos; Leatrice Vogel; Lily I Cheng; Marlene Orandle; Kanta Subbarao
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

5.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

6.  Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.

Authors:  Maikel V W van der Velden; Richard Fritz; Eva Maria Pöllabauer; Daniel Portsmouth; M Keith Howard; Thomas R Kreil; Thomas Dvorak; Sandor Fritsch; Timo Vesikari; Javier Diez-Domingo; Peter Richmond; Bee Wah Lee; Otfried Kistner; Hartmut J Ehrlich; P Noel Barrett; Gerald Aichinger
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

7.  T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine.

Authors:  Junwei Li; Maria T Arévalo; Yanping Chen; Shan Chen; Mingtao Zeng
Journal:  Int J Infect Dis       Date:  2014-08-27       Impact factor: 3.623

8.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

9.  Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses.

Authors:  Waleed H Mahallawi; Anand V Kasbekar; Maxwell S McCormick; Katja Hoschler; Nigel Temperton; Samuel C Leong; Helen Beer; Francesca Ferrara; Paul S McNamara; Qibo Zhang
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

10.  Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.

Authors:  Larisa Rudenko; Irina Kiseleva; Anatoly N Naykhin; Marianna Erofeeva; Marina Stukova; Svetlana Donina; Galina Petukhova; Maria Pisareva; Vera Krivitskaya; Michael Grudinin; Zhanna Buzitskaya; Irina Isakova-Sivak; Svetlana Kuznetsova; Natalie Larionova; Julia Desheva; Irina Dubrovina; Alexandra Nikiforova; John C Victor; Kathy Neuzil; Jorge Flores; Vadim Tsvetnitsky; Oleg Kiselev
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

View more
  5 in total

1.  Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.

Authors:  Kobporn Boonnak; Yumiko Matsuoka; Weijia Wang; Amorsolo L Suguitan; Zhongying Chen; Myeisha Paskel; Mariana Baz; Ian Moore; Hong Jin; Kanta Subbarao
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

2.  Antigenically Diverse Swine Origin H1N1 Variant Influenza Viruses Exhibit Differential Ferret Pathogenesis and Transmission Phenotypes.

Authors:  Joanna A Pulit-Penaloza; Joyce Jones; Xiangjie Sun; Yunho Jang; Sharmi Thor; Jessica A Belser; Natosha Zanders; Hannah M Creager; Callie Ridenour; Li Wang; Thomas J Stark; Rebecca Garten; Li-Mei Chen; John Barnes; Terrence M Tumpey; David E Wentworth; Taronna R Maines; C Todd Davis
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

3.  Could Environment Affect the Mutation of H1N1 Influenza Virus?

Authors:  Dong Jiang; Qian Wang; Zhihua Bai; Heyuan Qi; Juncai Ma; Wenjun Liu; Fangyu Ding; Jing Li
Journal:  Int J Environ Res Public Health       Date:  2020-04-29       Impact factor: 3.390

4.  Influenza in temperate and tropical Asia: a review of epidemiology and vaccinology.

Authors:  Barnaby Edward Young; M Chen
Journal:  Hum Vaccin Immunother       Date:  2020-02-04       Impact factor: 3.452

5.  Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system.

Authors:  Damien Friel; Mary Co; Thierry Ollinger; Bruno Salaun; Anne Schuind; Ping Li; Karl Walravens; Francis A Ennis; David W Vaughn
Journal:  Influenza Other Respir Viruses       Date:  2020-09-05       Impact factor: 4.380

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.